MKI67 and lung cancer: Patients with the higher inclusion levels of Ki67 exon 7 showed significantly poorer overall survival rate in bladder cancer (p = 0.02), colon cancer (p = 0.006), head and neck squamous cell carcinoma (p = 0.001), esophageal cancer (p = 0.02), lung cancer (p = 0.016), rectal cancer (p = 0.002), breast cancer (p = 0.006), cholangiocarcinoma (p = 0.032), and uveal melanoma (p = 0.043) (Figure 1B,D).